dr-3

ODN D-SL03, a class C CpG oligonucleotide, effectively stimulates peripheral blood mononuclear cells (PBMCs) to produce high levels of IFN-α. It activates human B cells, NK cells, and mononuclear cells, elevating the expression of CD80, CD86, and HLA-DR on PBMC subsets' surface. Additionally, ODN D-SL03 impedes tumor growth. Its sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' [1].

BIO5192 hydrate is a selective and potent integrin α4β1 (VLA-4) inhibitor (Kd<10 pM). BIO5192 hydrate selectively binds to α4β1 (IC50=1.8 nM) over a range of other integrins. BIO5192 hydrate results in a 30-fold increase in mobilization of murine hematopoietic stem and progenitors (HSPCs) over basal levels[1][2]. The combination of BIO5192 hydrate (1 mg/kg; i.v.) and Plerixafor (5 mg/kg; s.c.) exert an additive effect on progenitor mobilization[1].BIO5192 hydrate (30 mg/kg; s.c; bid; during days 5 through 14) delays paralysis associated with EAE (experimental autoimmune encephalomyelitis)[2].BIO5192 hydrate (1 mg/kg, i.v.) shows the terminal half-life is 1.1 hours. BIO5192 hydrate (3, 10, and 30 mg/kg; s.c.) shows half-lives of 1.7, 2.7, and 4.7 hours, respectively. The blood plasma curves show that the AUC for the s.c. route of administration increased about 2.5-fold from 5,460 h*ng/ml for the 3 mg/kg dose to 14,175 h*ng/ml for the 30 mg/kg[1]. Animal Model: C57BL/6J x 129Sv/J F1 mice[1] [1]. Ramirez P, et al. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood. 2009;114(7):1340‐1343. [2]. Leone DR, et al. An assessment of the mechanistic differences between two integrin alpha 4 beta 1 inhibitors, the monoclonal antibody TA-2 and the small molecule BIO5192, in rat experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther. 2003;305(3):1150-1162.

12-hydroxy Stearic acid is a hydroxy fatty acid produced by the hydrogenation of ricinoleic acid .1It is a low molecular weight gelator that self-assembles to form organogels.2Administration of paclitaxel in 12-hydroxy stearic acid-containing gel nanocarriers enhances tumor growth suppression in an H22 murine hepatocellular carcinoma model.3Formulations containing 12-hydroxy stearic acid have been used in cosmetic products as emollients. 1.Fameau, A.-L., and Rogers, M.A.The curious case of 12-hydroxystearic acid — the Dr. Jekyll & Mr. Hyde of molecular gelatorsCurr. Opin. Colloid Interface Sci.4568-82(2020) 2.Burkhardt, M., Noirez, L., and Gradzielski, M.Organogels based on 12-hydroxy stearic acid as a leitmotif: Dependence of gelation properties on chemical modificationsJ. Colloid Interface Sci.466369-376(2016) 3.He, W., Lv, Y., Zhao, Y., et al.Core-shell structured gel-nanocarriers for sustained drug release and enhanced antitumor effectInt. J. Pharm.484(1-2)163-171(2015)